nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—CYP2D6—Niacin—atherosclerosis	0.133	0.3	CbGbCtD
Dextroamphetamine—CYP2D6—Simvastatin—atherosclerosis	0.105	0.237	CbGbCtD
Dextroamphetamine—CYP2D6—Pravastatin—atherosclerosis	0.103	0.232	CbGbCtD
Dextroamphetamine—CYP2D6—Lovastatin—atherosclerosis	0.103	0.232	CbGbCtD
Dextroamphetamine—Accidental injury—Rosuvastatin—atherosclerosis	0.00756	0.0194	CcSEcCtD
Dextroamphetamine—Accidental injury—Lovastatin—atherosclerosis	0.0064	0.0165	CcSEcCtD
Dextroamphetamine—Viral infection—Ezetimibe—atherosclerosis	0.00615	0.0158	CcSEcCtD
Dextroamphetamine—Viral infection—Pravastatin—atherosclerosis	0.0053	0.0136	CcSEcCtD
Dextroamphetamine—Injury—Rosuvastatin—atherosclerosis	0.00528	0.0136	CcSEcCtD
Dextroamphetamine—Aspartame—TRPV1—atherosclerosis	0.0052	0.499	CrCbGaD
Dextroamphetamine—Muscle twitching—Niacin—atherosclerosis	0.00495	0.0127	CcSEcCtD
Dextroamphetamine—Injury—Lovastatin—atherosclerosis	0.00447	0.0115	CcSEcCtD
Dextroamphetamine—Injury—Pravastatin—atherosclerosis	0.00378	0.00973	CcSEcCtD
Dextroamphetamine—Depression—Rosuvastatin—atherosclerosis	0.00373	0.00959	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.0037	0.00952	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00363	0.00934	CcSEcCtD
Dextroamphetamine—Disturbance in sexual arousal—Niacin—atherosclerosis	0.0035	0.00901	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00346	0.00891	CcSEcCtD
Dextroamphetamine—Affect lability—Pravastatin—atherosclerosis	0.00342	0.0088	CcSEcCtD
Dextroamphetamine—Mood swings—Pravastatin—atherosclerosis	0.00329	0.00847	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Lovastatin—atherosclerosis	0.00327	0.00842	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00324	0.00834	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00321	0.00825	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.00318	0.00818	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.00314	0.00808	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.00313	0.00805	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Lovastatin—atherosclerosis	0.00308	0.00792	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Simvastatin—atherosclerosis	0.00306	0.00787	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00303	0.0078	CcSEcCtD
Dextroamphetamine—Depression—Simvastatin—atherosclerosis	0.00296	0.0076	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.00294	0.00756	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Niacin—atherosclerosis	0.00281	0.00723	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Pravastatin—atherosclerosis	0.00277	0.00712	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00274	0.00705	CcSEcCtD
Dextroamphetamine—Weight decreased—Pravastatin—atherosclerosis	0.00272	0.00699	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Lovastatin—atherosclerosis	0.00269	0.00692	CcSEcCtD
Dextroamphetamine—Tolazoline—HRH1—atherosclerosis	0.00268	0.257	CrCbGaD
Dextroamphetamine—Depression—Pravastatin—atherosclerosis	0.00267	0.00687	CcSEcCtD
Dextroamphetamine—Angioedema—Rosuvastatin—atherosclerosis	0.00267	0.00686	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.00266	0.00683	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00264	0.00679	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Ezetimibe—atherosclerosis	0.00264	0.00678	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Pravastatin—atherosclerosis	0.00263	0.00675	CcSEcCtD
Dextroamphetamine—Sweating—Niacin—atherosclerosis	0.00261	0.00671	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Pravastatin—atherosclerosis	0.00261	0.0067	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Simvastatin—atherosclerosis	0.00252	0.00647	CcSEcCtD
Dextroamphetamine—Infection—Rosuvastatin—atherosclerosis	0.00237	0.00609	CcSEcCtD
Dextroamphetamine—Tremor—Lovastatin—atherosclerosis	0.00232	0.00597	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Pravastatin—atherosclerosis	0.00227	0.00585	CcSEcCtD
Dextroamphetamine—Angioedema—Lovastatin—atherosclerosis	0.00226	0.00582	CcSEcCtD
Dextroamphetamine—Angioedema—Ezetimibe—atherosclerosis	0.00222	0.00571	CcSEcCtD
Dextroamphetamine—Tremor—Simvastatin—atherosclerosis	0.00217	0.00558	CcSEcCtD
Dextroamphetamine—Insomnia—Rosuvastatin—atherosclerosis	0.00216	0.00555	CcSEcCtD
Dextroamphetamine—Palpitations—Ezetimibe—atherosclerosis	0.00215	0.00552	CcSEcCtD
Dextroamphetamine—Angioedema—Simvastatin—atherosclerosis	0.00212	0.00544	CcSEcCtD
Dextroamphetamine—Chest pain—Lovastatin—atherosclerosis	0.00211	0.00542	CcSEcCtD
Dextroamphetamine—Anxiety—Lovastatin—atherosclerosis	0.0021	0.0054	CcSEcCtD
Dextroamphetamine—Dyspepsia—Rosuvastatin—atherosclerosis	0.0021	0.0054	CcSEcCtD
Dextroamphetamine—Hypertension—Ezetimibe—atherosclerosis	0.0021	0.00539	CcSEcCtD
Dextroamphetamine—Tension—Niacin—atherosclerosis	0.00209	0.00537	CcSEcCtD
Dextroamphetamine—Chest pain—Ezetimibe—atherosclerosis	0.00207	0.00532	CcSEcCtD
Dextroamphetamine—Nervousness—Niacin—atherosclerosis	0.00207	0.00531	CcSEcCtD
Dextroamphetamine—Dry mouth—Lovastatin—atherosclerosis	0.00206	0.0053	CcSEcCtD
Dextroamphetamine—Tension—Pravastatin—atherosclerosis	0.00206	0.00528	CcSEcCtD
Dextroamphetamine—Constipation—Rosuvastatin—atherosclerosis	0.00204	0.00524	CcSEcCtD
Dextroamphetamine—Nervousness—Pravastatin—atherosclerosis	0.00203	0.00523	CcSEcCtD
Dextroamphetamine—Dry mouth—Ezetimibe—atherosclerosis	0.00202	0.0052	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Lovastatin—atherosclerosis	0.00202	0.0052	CcSEcCtD
Dextroamphetamine—Infection—Lovastatin—atherosclerosis	0.00201	0.00516	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00198	0.0051	CcSEcCtD
Dextroamphetamine—Chest pain—Simvastatin—atherosclerosis	0.00197	0.00507	CcSEcCtD
Dextroamphetamine—Infection—Ezetimibe—atherosclerosis	0.00197	0.00506	CcSEcCtD
Dextroamphetamine—Anxiety—Simvastatin—atherosclerosis	0.00197	0.00505	CcSEcCtD
Dextroamphetamine—Tremor—Pravastatin—atherosclerosis	0.00196	0.00504	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00195	0.00501	CcSEcCtD
Dextroamphetamine—Angioedema—Niacin—atherosclerosis	0.00194	0.005	CcSEcCtD
Dextroamphetamine—Anorexia—Lovastatin—atherosclerosis	0.00193	0.00495	CcSEcCtD
Dextroamphetamine—Angioedema—Pravastatin—atherosclerosis	0.00191	0.00492	CcSEcCtD
Dextroamphetamine—Urticaria—Rosuvastatin—atherosclerosis	0.00189	0.00487	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Simvastatin—atherosclerosis	0.00189	0.00486	CcSEcCtD
Dextroamphetamine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00189	0.00485	CcSEcCtD
Dextroamphetamine—Palpitations—Niacin—atherosclerosis	0.00188	0.00483	CcSEcCtD
Dextroamphetamine—Infection—Simvastatin—atherosclerosis	0.00188	0.00483	CcSEcCtD
Dextroamphetamine—Insomnia—Lovastatin—atherosclerosis	0.00183	0.0047	CcSEcCtD
Dextroamphetamine—Hypertension—Pravastatin—atherosclerosis	0.00181	0.00465	CcSEcCtD
Dextroamphetamine—Anorexia—Simvastatin—atherosclerosis	0.0018	0.00463	CcSEcCtD
Dextroamphetamine—Dyspnoea—Lovastatin—atherosclerosis	0.0018	0.00463	CcSEcCtD
Dextroamphetamine—Insomnia—Ezetimibe—atherosclerosis	0.00179	0.00461	CcSEcCtD
Dextroamphetamine—Chest pain—Pravastatin—atherosclerosis	0.00178	0.00458	CcSEcCtD
Dextroamphetamine—Dyspepsia—Lovastatin—atherosclerosis	0.00178	0.00457	CcSEcCtD
Dextroamphetamine—Anxiety—Pravastatin—atherosclerosis	0.00178	0.00457	CcSEcCtD
Dextroamphetamine—Dry mouth—Niacin—atherosclerosis	0.00177	0.00455	CcSEcCtD
Dextroamphetamine—Dyspnoea—Ezetimibe—atherosclerosis	0.00177	0.00454	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00176	0.00452	CcSEcCtD
Dextroamphetamine—Decreased appetite—Lovastatin—atherosclerosis	0.00176	0.00452	CcSEcCtD
Dextroamphetamine—Dyspepsia—Ezetimibe—atherosclerosis	0.00175	0.00449	CcSEcCtD
Dextroamphetamine—Fatigue—Lovastatin—atherosclerosis	0.00174	0.00448	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Niacin—atherosclerosis	0.00174	0.00446	CcSEcCtD
Dextroamphetamine—Constipation—Lovastatin—atherosclerosis	0.00173	0.00444	CcSEcCtD
Dextroamphetamine—Decreased appetite—Ezetimibe—atherosclerosis	0.00172	0.00443	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00171	0.0044	CcSEcCtD
Dextroamphetamine—Asthenia—Rosuvastatin—atherosclerosis	0.00171	0.0044	CcSEcCtD
Dextroamphetamine—Insomnia—Simvastatin—atherosclerosis	0.00171	0.0044	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Pravastatin—atherosclerosis	0.00171	0.00439	CcSEcCtD
Dextroamphetamine—Fatigue—Ezetimibe—atherosclerosis	0.00171	0.00439	CcSEcCtD
Dextroamphetamine—Infection—Pravastatin—atherosclerosis	0.0017	0.00437	CcSEcCtD
Dextroamphetamine—Constipation—Ezetimibe—atherosclerosis	0.0017	0.00436	CcSEcCtD
Dextroamphetamine—Tachycardia—Niacin—atherosclerosis	0.00169	0.00436	CcSEcCtD
Dextroamphetamine—Dyspnoea—Simvastatin—atherosclerosis	0.00169	0.00433	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Niacin—atherosclerosis	0.00168	0.00431	CcSEcCtD
Dextroamphetamine—Dyspepsia—Simvastatin—atherosclerosis	0.00166	0.00428	CcSEcCtD
Dextroamphetamine—Anorexia—Niacin—atherosclerosis	0.00165	0.00425	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00165	0.00425	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Pravastatin—atherosclerosis	0.00165	0.00425	CcSEcCtD
Dextroamphetamine—Decreased appetite—Simvastatin—atherosclerosis	0.00164	0.00423	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00163	0.0042	CcSEcCtD
Dextroamphetamine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00163	0.0042	CcSEcCtD
Dextroamphetamine—Fatigue—Simvastatin—atherosclerosis	0.00163	0.00419	CcSEcCtD
Dextroamphetamine—Anorexia—Pravastatin—atherosclerosis	0.00163	0.00419	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00162	0.00417	CcSEcCtD
Dextroamphetamine—Constipation—Simvastatin—atherosclerosis	0.00162	0.00416	CcSEcCtD
Dextroamphetamine—Urticaria—Lovastatin—atherosclerosis	0.00161	0.00413	CcSEcCtD
Dextroamphetamine—Body temperature increased—Lovastatin—atherosclerosis	0.0016	0.00411	CcSEcCtD
Dextroamphetamine—Abdominal pain—Lovastatin—atherosclerosis	0.0016	0.00411	CcSEcCtD
Dextroamphetamine—Dizziness—Rosuvastatin—atherosclerosis	0.00158	0.00405	CcSEcCtD
Dextroamphetamine—Urticaria—Ezetimibe—atherosclerosis	0.00157	0.00405	CcSEcCtD
Dextroamphetamine—Insomnia—Niacin—atherosclerosis	0.00157	0.00404	CcSEcCtD
Dextroamphetamine—Abdominal pain—Ezetimibe—atherosclerosis	0.00157	0.00403	CcSEcCtD
Dextroamphetamine—Body temperature increased—Ezetimibe—atherosclerosis	0.00157	0.00403	CcSEcCtD
Dextroamphetamine—Dyspnoea—Niacin—atherosclerosis	0.00155	0.00398	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00155	0.00397	CcSEcCtD
Dextroamphetamine—Insomnia—Pravastatin—atherosclerosis	0.00155	0.00397	CcSEcCtD
Dextroamphetamine—Somnolence—Niacin—atherosclerosis	0.00154	0.00397	CcSEcCtD
Dextroamphetamine—Dyspepsia—Niacin—atherosclerosis	0.00153	0.00393	CcSEcCtD
Dextroamphetamine—Dyspnoea—Pravastatin—atherosclerosis	0.00152	0.00392	CcSEcCtD
Dextroamphetamine—Decreased appetite—Niacin—atherosclerosis	0.00151	0.00388	CcSEcCtD
Dextroamphetamine—Dyspepsia—Pravastatin—atherosclerosis	0.0015	0.00387	CcSEcCtD
Dextroamphetamine—Rash—Rosuvastatin—atherosclerosis	0.0015	0.00387	CcSEcCtD
Dextroamphetamine—Dermatitis—Rosuvastatin—atherosclerosis	0.0015	0.00386	CcSEcCtD
Dextroamphetamine—Urticaria—Simvastatin—atherosclerosis	0.0015	0.00386	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Niacin—atherosclerosis	0.0015	0.00385	CcSEcCtD
Dextroamphetamine—Abdominal pain—Simvastatin—atherosclerosis	0.00149	0.00384	CcSEcCtD
Dextroamphetamine—Body temperature increased—Simvastatin—atherosclerosis	0.00149	0.00384	CcSEcCtD
Dextroamphetamine—Headache—Rosuvastatin—atherosclerosis	0.00149	0.00384	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Lovastatin—atherosclerosis	0.00149	0.00383	CcSEcCtD
Dextroamphetamine—Decreased appetite—Pravastatin—atherosclerosis	0.00149	0.00382	CcSEcCtD
Dextroamphetamine—Fatigue—Pravastatin—atherosclerosis	0.00147	0.00379	CcSEcCtD
Dextroamphetamine—Constipation—Pravastatin—atherosclerosis	0.00146	0.00376	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Ezetimibe—atherosclerosis	0.00146	0.00376	CcSEcCtD
Dextroamphetamine—Asthenia—Lovastatin—atherosclerosis	0.00145	0.00373	CcSEcCtD
Dextroamphetamine—Asthenia—Ezetimibe—atherosclerosis	0.00142	0.00366	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Niacin—atherosclerosis	0.00142	0.00365	CcSEcCtD
Dextroamphetamine—Nausea—Rosuvastatin—atherosclerosis	0.00142	0.00364	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.0014	0.00359	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Simvastatin—atherosclerosis	0.00139	0.00358	CcSEcCtD
Dextroamphetamine—Diarrhoea—Lovastatin—atherosclerosis	0.00138	0.00356	CcSEcCtD
Dextroamphetamine—Urticaria—Niacin—atherosclerosis	0.00138	0.00355	CcSEcCtD
Dextroamphetamine—Body temperature increased—Niacin—atherosclerosis	0.00137	0.00353	CcSEcCtD
Dextroamphetamine—Abdominal pain—Niacin—atherosclerosis	0.00137	0.00353	CcSEcCtD
Dextroamphetamine—Urticaria—Pravastatin—atherosclerosis	0.00136	0.00349	CcSEcCtD
Dextroamphetamine—Asthenia—Simvastatin—atherosclerosis	0.00136	0.00349	CcSEcCtD
Dextroamphetamine—Diarrhoea—Ezetimibe—atherosclerosis	0.00136	0.00349	CcSEcCtD
Dextroamphetamine—Abdominal pain—Pravastatin—atherosclerosis	0.00135	0.00347	CcSEcCtD
Dextroamphetamine—Body temperature increased—Pravastatin—atherosclerosis	0.00135	0.00347	CcSEcCtD
Dextroamphetamine—Dizziness—Lovastatin—atherosclerosis	0.00134	0.00344	CcSEcCtD
Dextroamphetamine—Dizziness—Ezetimibe—atherosclerosis	0.00131	0.00337	CcSEcCtD
Dextroamphetamine—Diarrhoea—Simvastatin—atherosclerosis	0.00129	0.00333	CcSEcCtD
Dextroamphetamine—Vomiting—Lovastatin—atherosclerosis	0.00129	0.0033	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Niacin—atherosclerosis	0.00128	0.00329	CcSEcCtD
Dextroamphetamine—Rash—Lovastatin—atherosclerosis	0.00127	0.00328	CcSEcCtD
Dextroamphetamine—Dermatitis—Lovastatin—atherosclerosis	0.00127	0.00327	CcSEcCtD
Dextroamphetamine—Headache—Lovastatin—atherosclerosis	0.00127	0.00326	CcSEcCtD
Dextroamphetamine—Vomiting—Ezetimibe—atherosclerosis	0.00126	0.00324	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Pravastatin—atherosclerosis	0.00126	0.00324	CcSEcCtD
Dextroamphetamine—Dizziness—Simvastatin—atherosclerosis	0.00125	0.00321	CcSEcCtD
Dextroamphetamine—Rash—Ezetimibe—atherosclerosis	0.00125	0.00321	CcSEcCtD
Dextroamphetamine—Dermatitis—Ezetimibe—atherosclerosis	0.00125	0.00321	CcSEcCtD
Dextroamphetamine—Asthenia—Niacin—atherosclerosis	0.00125	0.0032	CcSEcCtD
Dextroamphetamine—Headache—Ezetimibe—atherosclerosis	0.00124	0.00319	CcSEcCtD
Dextroamphetamine—Asthenia—Pravastatin—atherosclerosis	0.00123	0.00315	CcSEcCtD
Dextroamphetamine—Vomiting—Simvastatin—atherosclerosis	0.0012	0.00309	CcSEcCtD
Dextroamphetamine—Nausea—Lovastatin—atherosclerosis	0.0012	0.00309	CcSEcCtD
Dextroamphetamine—Rash—Simvastatin—atherosclerosis	0.00119	0.00306	CcSEcCtD
Dextroamphetamine—Dermatitis—Simvastatin—atherosclerosis	0.00119	0.00306	CcSEcCtD
Dextroamphetamine—Diarrhoea—Niacin—atherosclerosis	0.00119	0.00305	CcSEcCtD
Dextroamphetamine—Headache—Simvastatin—atherosclerosis	0.00118	0.00304	CcSEcCtD
Dextroamphetamine—Nausea—Ezetimibe—atherosclerosis	0.00118	0.00303	CcSEcCtD
Dextroamphetamine—Diarrhoea—Pravastatin—atherosclerosis	0.00117	0.00301	CcSEcCtD
Dextroamphetamine—Dizziness—Niacin—atherosclerosis	0.00115	0.00295	CcSEcCtD
Dextroamphetamine—Dizziness—Pravastatin—atherosclerosis	0.00113	0.00291	CcSEcCtD
Dextroamphetamine—Nausea—Simvastatin—atherosclerosis	0.00112	0.00289	CcSEcCtD
Dextroamphetamine—Vomiting—Niacin—atherosclerosis	0.0011	0.00284	CcSEcCtD
Dextroamphetamine—Rash—Niacin—atherosclerosis	0.00109	0.00281	CcSEcCtD
Dextroamphetamine—Dermatitis—Niacin—atherosclerosis	0.00109	0.00281	CcSEcCtD
Dextroamphetamine—Headache—Niacin—atherosclerosis	0.00109	0.0028	CcSEcCtD
Dextroamphetamine—Vomiting—Pravastatin—atherosclerosis	0.00109	0.00279	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—TNF—atherosclerosis	0.00108	0.104	CrCbGaD
Dextroamphetamine—Rash—Pravastatin—atherosclerosis	0.00108	0.00277	CcSEcCtD
Dextroamphetamine—Dermatitis—Pravastatin—atherosclerosis	0.00108	0.00277	CcSEcCtD
Dextroamphetamine—Headache—Pravastatin—atherosclerosis	0.00107	0.00275	CcSEcCtD
Dextroamphetamine—Nateglinide—PPARG—atherosclerosis	0.00106	0.102	CrCbGaD
Dextroamphetamine—Nausea—Niacin—atherosclerosis	0.00103	0.00265	CcSEcCtD
Dextroamphetamine—Nausea—Pravastatin—atherosclerosis	0.00102	0.00261	CcSEcCtD
Dextroamphetamine—Nateglinide—ALB—atherosclerosis	0.000399	0.0383	CrCbGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL3—atherosclerosis	9.45e-05	0.000598	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—EDNRA—atherosclerosis	9.41e-05	0.000595	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCR2—atherosclerosis	9.41e-05	0.000595	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—F2—atherosclerosis	9.21e-05	0.000582	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SERPINE1—atherosclerosis	9.18e-05	0.000581	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GHRL—atherosclerosis	9.17e-05	0.00058	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—atherosclerosis	9.14e-05	0.000578	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLTP—atherosclerosis	9.02e-05	0.00057	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOA4—atherosclerosis	8.87e-05	0.000561	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—AGT—atherosclerosis	8.85e-05	0.00056	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	8.84e-05	0.000559	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NOS3—atherosclerosis	8.77e-05	0.000554	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—APOA1—atherosclerosis	8.58e-05	0.000542	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EDNRA—atherosclerosis	8.55e-05	0.000541	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCR2—atherosclerosis	8.55e-05	0.000541	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	8.52e-05	0.000539	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL3—atherosclerosis	8.4e-05	0.000531	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCR2—atherosclerosis	8.36e-05	0.000529	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—EDNRA—atherosclerosis	8.36e-05	0.000529	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GHRL—atherosclerosis	8.33e-05	0.000527	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CCL2—atherosclerosis	8.21e-05	0.000519	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—F2—atherosclerosis	8.18e-05	0.000517	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL4—atherosclerosis	8.17e-05	0.000517	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GHRL—atherosclerosis	8.15e-05	0.000515	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—KNG1—atherosclerosis	8.05e-05	0.000509	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AGTR1—atherosclerosis	8e-05	0.000506	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOA4—atherosclerosis	7.88e-05	0.000498	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—atherosclerosis	7.85e-05	0.000497	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LTA4H—atherosclerosis	7.82e-05	0.000495	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCG8—atherosclerosis	7.82e-05	0.000495	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL8—atherosclerosis	7.78e-05	0.000492	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—atherosclerosis	7.67e-05	0.000485	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOA2—atherosclerosis	7.64e-05	0.000483	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCR2—atherosclerosis	7.59e-05	0.00048	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EDNRA—atherosclerosis	7.59e-05	0.00048	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	7.57e-05	0.000479	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AKT1—atherosclerosis	7.51e-05	0.000475	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GHRL—atherosclerosis	7.4e-05	0.000468	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—atherosclerosis	7.39e-05	0.000468	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KNG1—atherosclerosis	7.31e-05	0.000462	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CCL2—atherosclerosis	7.29e-05	0.000461	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—UTS2—atherosclerosis	7.28e-05	0.000461	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AGTR1—atherosclerosis	7.27e-05	0.00046	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL4—atherosclerosis	7.26e-05	0.000459	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—KNG1—atherosclerosis	7.15e-05	0.000452	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AGTR1—atherosclerosis	7.11e-05	0.00045	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MMP9—atherosclerosis	7.03e-05	0.000445	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CX3CR1—atherosclerosis	6.98e-05	0.000442	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASR—atherosclerosis	6.98e-05	0.000442	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NFKB1—atherosclerosis	6.96e-05	0.00044	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CX3CL1—atherosclerosis	6.85e-05	0.000433	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MAPK8—atherosclerosis	6.84e-05	0.000433	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AKT1—atherosclerosis	6.82e-05	0.000431	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—atherosclerosis	6.8e-05	0.00043	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—EDN1—atherosclerosis	6.79e-05	0.000429	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOA2—atherosclerosis	6.78e-05	0.000429	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CCL5—atherosclerosis	6.73e-05	0.000426	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KNG1—atherosclerosis	6.49e-05	0.000411	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CNR2—atherosclerosis	6.49e-05	0.000411	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL8—atherosclerosis	6.49e-05	0.00041	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MMP3—atherosclerosis	6.48e-05	0.00041	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—UTS2—atherosclerosis	6.47e-05	0.000409	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	6.46e-05	0.000409	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AGTR1—atherosclerosis	6.46e-05	0.000408	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PRKCG—atherosclerosis	6.4e-05	0.000405	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VEGFA—atherosclerosis	6.32e-05	0.000399	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—STAT3—atherosclerosis	6.25e-05	0.000395	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CX3CR1—atherosclerosis	6.2e-05	0.000392	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASR—atherosclerosis	6.2e-05	0.000392	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCG1—atherosclerosis	6.18e-05	0.000391	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EDN1—atherosclerosis	6.16e-05	0.00039	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL5—atherosclerosis	6.11e-05	0.000387	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CX3CL1—atherosclerosis	6.08e-05	0.000385	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—EDN1—atherosclerosis	6.03e-05	0.000381	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CCL5—atherosclerosis	5.98e-05	0.000378	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MAPK3—atherosclerosis	5.97e-05	0.000378	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PRKCG—atherosclerosis	5.81e-05	0.000368	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LCAT—atherosclerosis	5.81e-05	0.000368	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—FABP4—atherosclerosis	5.81e-05	0.000368	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TGFB1—atherosclerosis	5.8e-05	0.000367	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VWF—atherosclerosis	5.79e-05	0.000366	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CNR2—atherosclerosis	5.77e-05	0.000365	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL8—atherosclerosis	5.76e-05	0.000364	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MMP3—atherosclerosis	5.75e-05	0.000364	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOC3—atherosclerosis	5.75e-05	0.000364	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atherosclerosis	5.74e-05	0.000363	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LDLR—atherosclerosis	5.72e-05	0.000361	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOA4—atherosclerosis	5.71e-05	0.000361	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PRKCG—atherosclerosis	5.69e-05	0.00036	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AGT—atherosclerosis	5.63e-05	0.000356	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP7A1—atherosclerosis	5.6e-05	0.000354	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL3—atherosclerosis	5.58e-05	0.000353	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EDN1—atherosclerosis	5.47e-05	0.000346	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL5—atherosclerosis	5.43e-05	0.000343	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NCF1—atherosclerosis	5.35e-05	0.000338	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—F2—atherosclerosis	5.2e-05	0.000329	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP27A1—atherosclerosis	5.18e-05	0.000328	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PRKCG—atherosclerosis	5.16e-05	0.000327	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VWF—atherosclerosis	5.14e-05	0.000325	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AGT—atherosclerosis	5.11e-05	0.000323	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOC3—atherosclerosis	5.11e-05	0.000323	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LDLR—atherosclerosis	5.08e-05	0.000321	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCR2—atherosclerosis	5.05e-05	0.000319	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EDNRA—atherosclerosis	5.05e-05	0.000319	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CYBA—atherosclerosis	5.03e-05	0.000318	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AGT—atherosclerosis	5e-05	0.000316	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CG—atherosclerosis	4.98e-05	0.000315	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL3—atherosclerosis	4.96e-05	0.000314	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PLAT—atherosclerosis	4.92e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GHRL—atherosclerosis	4.92e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PARP1—atherosclerosis	4.92e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOA2—atherosclerosis	4.91e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALOX15—atherosclerosis	4.91e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	4.91e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	4.91e-05	0.000311	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCG5—atherosclerosis	4.85e-05	0.000307	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NCF1—atherosclerosis	4.75e-05	0.0003	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—F2—atherosclerosis	4.73e-05	0.000299	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LPA—atherosclerosis	4.69e-05	0.000296	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—F2—atherosclerosis	4.62e-05	0.000292	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AGT—atherosclerosis	4.54e-05	0.000287	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—BGN—atherosclerosis	4.54e-05	0.000287	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CG—atherosclerosis	4.52e-05	0.000286	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOA5—atherosclerosis	4.49e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EDNRA—atherosclerosis	4.49e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCR2—atherosclerosis	4.49e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CYBA—atherosclerosis	4.47e-05	0.000282	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CG—atherosclerosis	4.42e-05	0.00028	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PLAT—atherosclerosis	4.37e-05	0.000276	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GHRL—atherosclerosis	4.37e-05	0.000276	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PARP1—atherosclerosis	4.37e-05	0.000276	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—atherosclerosis	4.37e-05	0.000276	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	4.32e-05	0.000273	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KNG1—atherosclerosis	4.32e-05	0.000273	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AGTR1—atherosclerosis	4.29e-05	0.000272	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CCL2—atherosclerosis	4.21e-05	0.000266	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—F2—atherosclerosis	4.2e-05	0.000265	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PLG—atherosclerosis	4.18e-05	0.000265	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALOX5—atherosclerosis	4.18e-05	0.000264	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKT1—atherosclerosis	4.03e-05	0.000255	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CG—atherosclerosis	4.02e-05	0.000254	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SOCS3—atherosclerosis	3.96e-05	0.000251	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KNG1—atherosclerosis	3.84e-05	0.000243	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP3—atherosclerosis	3.83e-05	0.000242	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AGTR1—atherosclerosis	3.81e-05	0.000241	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF2—atherosclerosis	3.81e-05	0.000241	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NAMPT—atherosclerosis	3.75e-05	0.000237	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CCL2—atherosclerosis	3.74e-05	0.000237	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LIPC—atherosclerosis	3.72e-05	0.000235	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PLG—atherosclerosis	3.72e-05	0.000235	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOC3—atherosclerosis	3.7e-05	0.000234	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOB—atherosclerosis	3.7e-05	0.000234	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LDLR—atherosclerosis	3.68e-05	0.000232	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL8—atherosclerosis	3.67e-05	0.000232	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EDN1—atherosclerosis	3.64e-05	0.00023	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL5—atherosclerosis	3.61e-05	0.000228	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CETP—atherosclerosis	3.59e-05	0.000227	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LPL—atherosclerosis	3.53e-05	0.000223	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SOCS3—atherosclerosis	3.52e-05	0.000223	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SCARB1—atherosclerosis	3.44e-05	0.000217	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PRKCG—atherosclerosis	3.43e-05	0.000217	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP3—atherosclerosis	3.4e-05	0.000215	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF2—atherosclerosis	3.38e-05	0.000214	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SPP1—atherosclerosis	3.34e-05	0.000212	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL8—atherosclerosis	3.33e-05	0.000211	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOB—atherosclerosis	3.29e-05	0.000208	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL8—atherosclerosis	3.26e-05	0.000206	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HMGCR—atherosclerosis	3.25e-05	0.000205	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EDN1—atherosclerosis	3.23e-05	0.000204	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL5—atherosclerosis	3.21e-05	0.000203	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LPL—atherosclerosis	3.14e-05	0.000198	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDGFB—atherosclerosis	3.09e-05	0.000196	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	3.05e-05	0.000193	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AGT—atherosclerosis	3.02e-05	0.000191	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	2.97e-05	0.000188	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LEP—atherosclerosis	2.96e-05	0.000187	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOE—atherosclerosis	2.96e-05	0.000187	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	2.96e-05	0.000187	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CAV1—atherosclerosis	2.93e-05	0.000185	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APOA1—atherosclerosis	2.93e-05	0.000185	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.89e-05	0.000183	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ESR1—atherosclerosis	2.83e-05	0.000179	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—F2—atherosclerosis	2.79e-05	0.000177	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	2.75e-05	0.000174	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AGT—atherosclerosis	2.68e-05	0.00017	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CG—atherosclerosis	2.67e-05	0.000169	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LEP—atherosclerosis	2.63e-05	0.000166	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOE—atherosclerosis	2.63e-05	0.000166	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	2.61e-05	0.000165	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	2.6e-05	0.000164	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAPK3—atherosclerosis	2.56e-05	0.000162	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—INS—atherosclerosis	2.53e-05	0.00016	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	2.51e-05	0.000159	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCL2—atherosclerosis	2.49e-05	0.000157	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HMOX1—atherosclerosis	2.48e-05	0.000157	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—F2—atherosclerosis	2.48e-05	0.000157	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1—atherosclerosis	2.45e-05	0.000155	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOB—atherosclerosis	2.38e-05	0.00015	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	2.37e-05	0.00015	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SERPINE1—atherosclerosis	2.32e-05	0.000147	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTM1—atherosclerosis	2.31e-05	0.000146	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	2.27e-05	0.000144	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LPL—atherosclerosis	2.27e-05	0.000144	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—INS—atherosclerosis	2.25e-05	0.000142	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	2.22e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPX1—atherosclerosis	2.22e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	2.21e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	2.17e-05	0.000137	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CD36—atherosclerosis	2.16e-05	0.000136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	2.06e-05	0.00013	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTHFR—atherosclerosis	2.05e-05	0.000129	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPARA—atherosclerosis	2.01e-05	0.000127	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	1.97e-05	0.000125	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	1.97e-05	0.000124	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AGT—atherosclerosis	1.94e-05	0.000123	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOE—atherosclerosis	1.9e-05	0.00012	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	1.9e-05	0.00012	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CAV1—atherosclerosis	1.89e-05	0.000119	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APOA1—atherosclerosis	1.88e-05	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	1.87e-05	0.000118	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	1.78e-05	0.000113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	1.76e-05	0.000111	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	1.75e-05	0.00011	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	1.73e-05	0.000109	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	1.73e-05	0.000109	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.72e-05	0.000109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	1.69e-05	0.000107	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	1.66e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPARG—atherosclerosis	1.66e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—INS—atherosclerosis	1.63e-05	0.000103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	1.6e-05	0.000101	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	1.58e-05	0.0001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	1.58e-05	9.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	1.56e-05	9.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	1.54e-05	9.72e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	1.53e-05	9.69e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	1.51e-05	9.56e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALB—atherosclerosis	1.49e-05	9.43e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	1.47e-05	9.27e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NOS3—atherosclerosis	1.43e-05	9.02e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	1.42e-05	8.97e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	1.41e-05	8.89e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	1.34e-05	8.49e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.3e-05	8.25e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	1.3e-05	8.24e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.11e-05	6.99e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.02e-05	6.45e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	9.82e-06	6.21e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	9.06e-06	5.73e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AKT1—atherosclerosis	6.56e-06	4.15e-05	CbGpPWpGaD
